article Open AccessTop 1% cited
American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials
Annals of the Rheumatic Diseases · 2011 · Vol. 70(3) · pp. 404–413
David T. Felson(University of Manchester)Josef S Smolen(Klinik Hietzing)George A. Wells(University of Ottawa)Bin Zhang(Amsterdam UMC Location VUmc)L. van Tuyl(Boston University)Julia Funovits(Boston University)Daniel Aletaha(Medical University of Vienna)Cornelia F Allaart(Leiden University Medical Center)Joan M. Bathon(Johns Hopkins University)Stefano Bombardieri(University of Pisa)Peter Brooks(University of Melbourne)D. Andrew Brown(University of York)Marco Matucci‐Cerinic(University of Florence)Hyon K. Choi(University of Ottawa)Bernard Combe(Centre Hospitalier Universitaire de Montpellier)Maarten de WitMaxime Dougados(Assistance Publique – Hôpitaux de Paris)Paul Emery(NIHR Leeds Musculoskeletal Biomedical Research Unit)Daniel E. Fürst(University of California, Los Angeles)Juan J. Gómez‐Reino(Complejo Hospitalario Universitario de Santiago)Gillian Hawker(Women's College Hospital)Edward Keystone(University of Toronto)Dinesh Khanna(University of California, Los Angeles)John Kirwan(University of Bristol)Tore K. Kvien(Diakonhjemmet Hospital)Robert Landewé(Maastricht University Medical Centre)Joachim Listing(German Rheumatism Research Centre)Kaleb Michaud(The National Databank for Rheumatic Diseases)E. Martín‐Mola(Hospital Universitario La Paz)Pamela MontieTheodore Pincus(New York University)Pamela Richards(At Bristol)Jeffrey Siegel(United States Food and Drug Administration)Lee S. SimonTuulikki Sokka(Central Finland Health Care District)Vibeke Strand(Palo Alto University)Peter Tugwell(Medical University of Vienna)Alan Tyndall(University of Basel)Désirée van der Heijde(Leiden University Medical Center)Suzanne Verstappen(University of Manchester)Barbara WhiteFrederick Wolfe(University of Kansas)A. Zink(German Rheumatism Research Centre)Maarten Boers✉(Amsterdam UMC Location VUmc)
Rheumatoid Arthritis Research and TherapiesLymphoma Diagnosis and TreatmentSystemic Lupus Erythematosus ResearchMedicineRheumatismRheumatologyRheumatoid arthritisInternal medicinePhysical therapyClinical trialFamily medicine
MeSH terms
Arthritis, RheumatoidClinical Trials as TopicData CollectionEuropeHumansTerminology as TopicPrognosisRemission InductionSeverity of Illness IndexUnited StatesTreatment OutcomeAntirheumatic AgentsEndpoint Determination
Citations
766
FWCI
42.99
field-weighted impact
References
76
Percentile
100%
vs. same field & year
Citations per year
Cited by
Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
Annals of the Rheumatic Diseases · 2015 · 1,431 citations
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
Annals of the Rheumatic Diseases · 2022 · 1,636 citations
European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update
Annals of the Rheumatic Diseases · 2016 · 910 citations
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Annals of the Rheumatic Diseases · 2017 · 5,757 citations
American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials
Annals of the Rheumatic Diseases · 2011 · 766 citations
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
Annals of the Rheumatic Diseases · 2013 · 1,756 citations
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Annals of the Rheumatic Diseases · 2020 · 2,709 citations
References
Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial
Arthritis & Rheumatism · 2003 · 1,756 citations
Measurement of patient outcome in arthritis
Arthritis & Rheumatism · 1980 · 4,364 citations
The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
Arthritis & Rheumatism · 2005 · 1,780 citations
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trial
Arthritis & Rheumatism · 2004 · 1,168 citations
Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis
Arthritis & Rheumatism · 1995 · 6,175 citations
REMISSION IN A PROSPECTIVE STUDY OF PATIENTS WITH RHEUMATOID ARTHRITIS. AMERICAN RHEUMATISM ASSOCIATION PRELIMINARY REMISSION CRITERIA IN RELATION TO THE DISEASE ACTIVITY SCORE
Lara D. Veeken · 1995 · 376 citations
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
Annals of the Rheumatic Diseases · 2008 · 1,104 citations
A simplified disease activity index for rheumatoid arthritis for use in clinical practice
Lara D. Veeken · 2003 · 1,048 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.